Surface-induced thrombosis hinges on the generation of thrombin, a central mediator that amplifi es the intrinsic coagulation cascade, crosslinks fi brin, and activates platelets. [ 12 , 13 ] First demonstrated in 1963, [ 14 ] heparin immobilization has been hypothesized to mimic the antithrombin activity of cell surface heparan sulfate proteoglycans (HSPG) expressed by the endothelium. [ 15 ] Recent randomized clinical trials show that heparin-modifi ed surfaces substantially improved the clinical outcomes of expanded poly(tetrafl uoroethylene) (ePTFE) vascular grafts in lower extremity revascularization. Superior 1-year results have been recently reported for heparin-bonded ePTFE (Propaten) when compared with non-coated ePTFE. [ 16 ] Preliminary analysis of heparin-bonded ePTFE covered stents in the superfi cial femoral artery suggests a similar effect. [ 17 , 18 ] Attenuation of thrombin production at the blood-contacting interface, therefore, may be a critical step in the design of blood-compatible materials that improve the clinical performance of blood-contacting implants.
The physiological role of heparin, produced primarily by mast cells, in hemostasis remains unclear [ 19 ] as the majority of anticoagulantly active HSPG is not in direct contact with fl owing blood [ 20 ] and knock-out mice lacking the specifi c pentasaccharide sequence that inhibits thrombin do not exhibit a procoagulant phenotype. [ 21 ] In contrast, TM is the major vasculoprotective molecule localized on the endothelial cell surface and defects therein increase the risk of thromboembolism, as well as infl ammatory disorders. [ 22 ] By forming a stoichiometric 1:1 complex with thrombin, TM sequesters thrombin's prothrombotic activity, and simultaneously accelerates thrombin's catalytic activity to generate activated protein C (aPC) by 1000-fold. aPC inhibits the upstream proteases necessary for amplifying thrombin production and represents the primary physiological mechanism, which regulates hemostasis. [ 23 , 24 ] Clinical implementation of strategies reported to date on the immobilization of TM, [25] [26] [27] [28] [29] [30] [31] as well as other proteins in therapeutic and diagnostic applications, has been primarily limited by two main factors: the inherent reduction in activity associated with schemes that non-specifi cally react with free amino, carboxyl, or thiol motifs contained near the catalytically active site, and the necessity for terminal sterilization, which in the medical device industry mainly comprise either ethylene oxide (EtO) or radiation that often perturb the chemical structure and activity of surface-bound biomolecules. [32] [33] [34] We were fi rst to demonstrate a bioorthogonal strategy to site-specifi cally tether recombinant human TM via a single C-terminal azide motif (TM-N 3 ) by Staudinger Ligation on the luminal surface of 4 mm i.d. ePTFE grafts that preserved the therapeutic activity of TM to catalyze aPC generation. [ 35 ] In principle, immobilization of wileyonlinelibrary.com 31 
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www.advhealthmat.de TM on sterilized surfaces with stable anchor sites may provide an alternative to terminal sterilization to manufacture an offthe-shelf product. However, the limited yield and scalability of auxotrophic incorporation of azido-alanine in TM-N 3 as well as the propensity of triphenylphosphines to degrade by air oxidation [ 36 ] in our previous report would prohibit the clinical translation of such an approach.
SrtA is a calcium-dependent cysteine transpeptidase found in Staphylococcus aureus and other Gram-positive bacteria that anchors proteins containing a C-terminal LPXTG motif (where X denotes any amino acid) by breaking the threonine-glycine bond and forming a new amide bond with oligoglycine-linked molecules. [37] [38] [39] Site-specifi c SrtA transpeptidation of synthetic nucleophiles may be a more effi cient alternative to unnatural amino acid approaches [ 40 ] to incorporate any of a number of functionalities, such as biotin, fl uorophores, and azides, to the termini of recombinant proteins in one step. [ 41 , 42 ] We generated a recombinant human TM fragment ( Figure S1 , Supporting Information) containing the minimal functional domains for antithrombotic activity [ 43 , 44 ] and a C-terminal LPETG sequence (TM LPETG ) that facilitated subsequent C-terminal fusion with a biotinylated pentaglycine peptide probe (Gly 5 -biotin) and wildtype (WT) SrtA ( Figure S2 , Supporting Information). TM LPETG exhibited similar catalytic activity to generate aPC in the presence of thrombin and calcium compared with previous batches of TM generated in our lab. [ 44 ] However, high molar excess of WT SrtA ( > 2 molar equiv) and Gly 5 -biotin ( > 10 molar equiv), as well as long reaction times (20 h), were required to drive TM LPETG biotinylation yields ( Figure S3 , Supporting Information). Our observations are in agreement with other reported SrtA-catalyzed protein labeling applications, which were similarly limited by the low catalytic activity of WT SrtA. [ 41 , 42 ] In addition, we confi rmed previous reports showing the suitability of alkylamine nucleophile substrates for SrtA [ 42 , 45 ] by demonstrating WT SrtA-catalyzed PEGylation of TM LPETG in the presence of 100 molar equiv of 5 kDa NH 2 -PEG, which achieved ≈ 80% yield after 20 h ( Figure S4 , Supporting Information). Despite their lower effi ciency as nucleophiles, the relative synthetic simplicity of alkylamine compared with oligoglycine derivatives may further improve the commercial scalability and scope of suitable substrates for SrtA-catalyzed protein labeling.
The recent development of a general yeast display system has facilitated directed evolution of WT SrtA to generate a SrtA pentamutant (eSrtA), which exhibited 120-fold increase in catalytic activity, [ 46 ] and enabled the routine preparation of recombinant proteins that contain a single C-terminal α -thioester. [ 47 ] We hypothesized that eSrtA may facilitate rapid labeling of TM LPETG with a single azide motif using the commercially available alkylamine derivative NH 2 -PEG 3 -N 3 to generate TM-N 3 ( Figure 1 a) . As shown in Figure 2 a, eSrtA dramatically improved the PEGylation effi ciency of TM LPETG with 100 molar equiv of 5 kDa NH 2 -PEG probe as compared with WT SrtA, achieving nearly 80% yield after 2 h with 0.1 molar equiv eSrtA. This rapid one-step reaction may be broadly applied to site-specifi cally PEGylate LPETG-tagged recombinant protein therapeutics, which has been routinely performed to optimize half-life and biostability. [ 48 , 49 ] Notably, the reaction of TM LPETG with 1 or 10 molar equiv 5 kDa NH 2 -PEG for 2 h yielded minimal TM-PEG product, and no major TM multimer products formed at these conditions ( Figure S5 , Supporting Information). These observations indicate minimal non-specifi c transpeptidation with exposed primary amines on TM LPETG despite the enhanced catalytic activity of eSrtA. eSrtA was equally effi cient in catalyzing the biotinylation of TM LPETG (Figure 2 b) in the presence of 100 molar equiv Gly 5 -biotin and NH 2 -PEG 3 -biotin, demonstrating equivalency of alkylamines as compared with oligoglycines for eSrtA transpeptidation when reacted in high molar excess. Under optimal reaction conditions, 0.1 equiv eSrtA and 100-fold molar excess NH 2 -PEG 3 -N 3 relative to TM LPETG yielded a TM-N 3 conjugate in 2 h, which exhibited selective reactivity with alkyne probes (Figure 2 c) . As the high excess of alkylamine derivatives could be removed or recovered by established dialysis methods due to their small molecular weight, and Histagged eSrtA could be effi ciently removed by applying the crude reaction mixture onto a metal-affi nity column ( Figure S6 , Supporting Information), commercial scale-up of TM-N 3 production by eSrtA transpeptidation should be feasible. Optimization of strained alkynes has yielded variants that exhibit substantially higher reaction kinetics than Staudinger Ligation, while maintaining bioorthogonality to undergo cycloaddition with azide without copper catalysis. [ 50 , 51 ] Dibenzocyclooctyne (DIBO) has been among the most well-characterized strained alkynes and has been commercialized for cell imaging applications. [ 52 ] We synthesized a DIBO-PEG 11 -NH 2 linker that enabled the activation of the luminal surface of 4 mm i.d. ePTFE vascular grafts, as well as solvent-cast polyurethane (PU) fi lms, with DIBO anchor groups using an approach reported previously [ 35 ] and outlined in Figure 1 b. Commercial ePTFE grafts activated with DIBO reacted specifi cally with Rh-N 3, as verifi ed visually ( Figure S7 , Supporting Information). Signifi cantly, we demonstrated that EtO sterilization of DIBOmodifi ed surfaces did not impair their capacity to bind azide derivatives. Figure 3 a shows the capacity of DIBO to specifi cally react with rhodamine azide (Rh-N 3 ) was not diminished following EtO sterilization of DIBO-modifi ed PU fi lms. Quantitative measurement of surface biotin density in Figure 3 b confi rmed no signifi cant change in DIBO reactivity with azide-PEG 3 -biotin following EtO sterilization of DIBO-modifi ed ePTFE grafts. Covalent immobilization of TM-N 3 on EtO-sterilized ePTFE grafts modifi ed with DIBO maintained similar levels of catalytic activity to generate ≈ 15 ng aPC cm − 2 min − 1 as TM-N 3 immobilized on non-sterile DIBO-modifi ed grafts. Collectively, these results support the feasibility of immobilizing TM-N 3 on sterilized DIBO-modifi ed surfaces that would be carried out in the operating room prior to implantation. Similar pointof-care approaches have been described, for example, electrospinning of polymer wraps for autologous vein grafts, [ 53 ] as well as endothelial cell seeding of ePTFE grafts [ 54 ] prior to implantation, though these methods may carry a higher risk of microbial contamination.
Due to the lack of clinical data that establish the minimal aPC fl ux required to reduce risk of graft thrombosis, the therapeutic characteristics of TM-modifi ed ePTFE grafts was evaluated in an animal model. Chronic arteriovenous shunt models in baboons, whose hemostatic systems most closely mirror that of man, are routinely used to assess the thrombogenicity of blood-contacting materials under dynamic fl ow in vivo. [55] [56] [57] Due to tissue injury at the graft anastomosis, which results in exposure of highly thrombogenic tissue factor and collagen motifs to fl owing blood, [ 13 ] we devised a multi-compartment shunt confi guration that inserted an upstream Dacron graft segment that serves as a thrombogenic stress to test the therapeutic activity of aPC generated in a downstream TM-modifi ed graft segment ( Figure 4 a) . We postulated that the Dacron segment may provide a more clinically relevant test bed by reconstituting the in vivo thrombogenic stress exerted on implanted graft materials. Thrombogenicity of materials was evaluated by measuring the real-time deposition of radio-labeled autologous platelets on the Dacron was prone to platelet deposition as evident by steady accumulation over a 1 h perfusion period (Figure 4 b) , which was similar to previous reports. [ 58 , 59 ] TM-modifi ed ePTFE graft segments reduced platelet deposition by ≈ 80% (Figure 4 c) when compared with unmodifi ed grafts ( n = 5, p < 0.01). The therapeutic effi cacy of TM was signifi cantly greater than the commercial heparin coating, which resulted in a ≈ 50% reduction in platelet deposition relative to unmodifi ed grafts ( n = 5, p < 0.05). Minimal deposition of platelets on heparin-modifi ed ePTFE in non-human primates had previously been reported in shunt confi gurations that lacked the upstream Dacron segment, [ 60 ] but our current studies suggest that the antithrombin III activity catalyzed by heparin may be overwhelmed in the presence of a high upstream thrombogenic source. Given the many factors that dictate the durability of an arterial substitute, the benefi t afforded by TM immobilization will need to be evaluated in long-term surgically implanted bypass confi gurations in vivo. [ 61 ] In summary, we have demonstrated the feasibility of covalently immobilizing TM-N 3 on EtO-sterilized ePTFE grafts as a point-of-care delivery scheme, which may be a key step in the clinical translation of biologically active fi lms for permanent implants as a sterile off-the-shelf product. Signifi cantly, we demonstrated the superior blood-contacting properties of TM-modifi ed vascular grafts as compared with current commercial heparin-modifi ed grafts in a primate model of acute graft thrombosis. Moreover, we have optimized the scalability of producing TM-N 3 by rapid one-step eSrtA transpeptidation of alkylamine azide, and demonstrated the suitability of this approach to site-specifi cally PEGylate or biotinylate TM. Based on growing reports to date on the application of WT SrtA, the enhanced reactivity of eSrtA may be a key enabling step in the industrial scaling of these strategies.
Experimental Section
Materials : All reagents were purchased from Aldrich, St Louis, and used without further purifi cation unless otherwise noted. Expression and purifi cation of recombinant TM LPETG and sortases, as well as solution phase sortase transpeptidation reactions are detailed in the Supporting Information. Gly 5 -biotin was obtained from Genscript, Piscataway and used without further purifi cation.
Synthesis of DIBO-PEG 11 -NH 2 : The activated DIBO was synthesized according to a previously published protocol. [ 52 ] DIBO-PEG 11 -NH 2 was synthesized by reaction between the activated DIBO and t -Boc-N-amido-dPEG 11 -amine (Quanta BioDesign, Powell) followed by TFA deprotection, as detailed previously. [ 62 ] Modifi cation of ePTFE Grafts : 5% (w/v) Elasthane 80A (Polymer Tech, Berkeley) in N,Ndimethylformamide (DMF) was extruded through 4 mm i.d. ePTFE thin wall vascular grafts (Bard, Tempe) and dried under vacuum at 60 ° C for 20 min. Additional PU was deposited in multiple fl ow-through/drying cycles over the base layer, and dried overnight under vacuum at 60 ° C. PU-coated grafts were inserted into tubular rotary reactors, as described previously for surface reactions. [ 35 ] Grafts were fi rst reacted with HDI (16%, v/v) and TEA (4%, v/v) in toluene at 50 ° C for 1 h and rinsed in toluene for 6 h. Isocyanate activated grafts were reacted with DIBO-PEG 11 -NH 2 linker (5 mg mL − 1 ) and DMSO (1%, v/v) in toluene at 40 ° C overnight, rinsed with toluene for 6 h, and dried under vacuum at 25 ° C overnight. Standard EtO sterilization was carried out at the Beth Israel Deaconess Medical Center Central Processing (Boston MA). DIBO-activated grafts were reacted with 1 mg mL − 1 tetramethylrhodamine-5-carbonyl azide (Invitrogen, Carlsbad) in 1:4 tert-butanol/TBS at 37 ° C for 24 h followed by rinsing in methanol for 2 d, 1 × 10 − 3 M biotin-PEG 3 -N 3 (Pierce, Rockford) in TBS at 37 ° C for 24 h followed by rinsing in TBS for 24 h, or 20 × 10 − 6 M TM-N 3 in Tris buffered saline (TBS, 20 × 10 − 3 M Tris, 100 × 10 − 3 M NaCl, pH 7.5) at 37 ° C for 24 h and rinsed with TBS for 24 h. Grafts coated with PU and activated with DIBO were reacted with rhodamine B or TM LPETG as controls.
Modifi cation of Polyurethane Films : Thin clear PU fi lms were solvent cast by drying 12.5% (w/v) PU in DMF for 24 h at 60 ° C under vacuum. Films were subjected to isocyanate, DIBO, and rhodamine reactions in a glass vial using identical conditions as graft substrates, and characterized by UV-vis spectroscopy (Cary 50 Bio UV-vis spectrophotometer, Varian).
TM Graft Cofactor Activity Assay : A 4 mm graft segment was incubated in 200 μ L of 0.2 × 10 − 6 M human protein C (Calbiochem, Gibbstown), 5 × 10 − 3 M calcium chloride, and 2 × 10 − 9 M human α -thrombin (Haematologic Technologies, Essex Junction) in Tris buffer (20 × 10 − 3 M Tris, 100 × 10 − 3 M NaCl, pH 7.5) with 0.1% bovine serum albumin (BSA) at 37 ° C for 1 h, and quenched with 2 IU mL − 1 human anti-thrombin III (American Diagnostica, Stamford) for 5 min. The generation of aPC was quantifi ed using 0.2 × 10 − 3 M of an enzymatically digestible chromogenic substrate, Spectrozyme PCa (American Diagnostica). All assay reactions were run in a 96-well plate, per manufacturer's instructions (Pierce). Moles of biotin motifs bound to graft samples were determined using a standard curve generated by known concentrations of streptavidin-HRP incubated with TMB substrate. At the end of each assay, graft segments were fl attened between glass slides and scanned at 600 dpi using a HP ScanJet 5370C scanner and the reactive area of each test sample was measured using ImageJ software.
In Vivo Baboon Arteriovenous Shunt Model : Chronic exteriorized Silastic tubings were implanted in male baboons, as described previously. [ 63 , 64 ] All studies were approved by the Institutional Animal Care and Use Committee at Oregon Health and Science University. Mean blood fl ow rate through the shunt was measured continuously using a Doppler ultrasonic fl ow meter and held constant by an external screw clamp at 100 mL min − 1 . Autologous platelets were radiolabeled 1 day prior to shunt study with Indium-111 oxine and re-injected into the baboon. Platelet deposition in the individual compartments of the shunt assembly was measured over a 60-min perfusion period using a high sensitivity 99Tc collimator and scintillation camera (GE 400T, General Electric) imaging of the 172 keV 111 In photon peak at 5-min intervals. Thrombogenic devices were assembled and inserted into shunts, as detailed previously. [ 35 ] Statistical Analysis : Two-tailed student's t-test assuming unequal variances was used to test for statistical signifi cance between the means of two groups.
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